Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab-Reference-Cited by-同舟云学术

Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab

Published:2024-05 Issue: Volume:127-128 Page:110761
ISSN:0009-9120
Container-title:Clinical Biochemistry
language:en
Short-container-title:Clinical Biochemistry

Author:

Jimenez Adam^ORCID,Scholl Ashley Rose,Wang Bangchen,Schilke Michael,Carlsen Eric D.

Publisher

Elsevier BV

Reference27 articles.

1. Expression of daratumumab and elotuzumab migration by capillary electrophoresis relative to transferrin improves precision of their identification;Huls;J. Appl. Lab. Med.,2020

2. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N. Engl. J. Med.,2015

3. Characterization of casirivimab plus imdevimab, sotrovimab, and bamlanivimab plus etesevimab-derived interference in serum protein electrophoresis and immunofixation electrophoresis;Scholl;J. Appl. Lab. Med.,2022

4. Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab;Tang;Am. J. Clin. Pathol.,2018

5. Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins;Ruinemans-Koerts;Clin. Chem. Lab. Med.,2014

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable therapeutic antibody in serum as potential predictive factor of response to anti-CD38 therapy in non-IgG-k myeloma patients;Experimental Hematology & Oncology;2024-08-06